




Instance: composition-en-74cee07ffddb72142d80fc4c20efe6f2
InstanceOf: CompositionUvEpi
Title: "Composition for tavneos Package Leaflet"
Description:  "Composition for tavneos Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpcda3d6c6b3d95392dfae933ed4fdbdcb)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - tavneos"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Tavneos is and what it is used for </li>
<li>What you need to know before you take Tavneos </li>
<li>How to take Tavneos </li>
<li>Possible side effects </li>
<li>How to store Tavneos </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What tavneos is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What tavneos is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is Tavneos? </p>
<p>Tavneos contains the active substance avacopan, which attaches to a specific protein in the body, 
called complement 5a receptor. </p>
<p>What is Tavneos used for? </p>
<p>Tavneos is used to treat adults with a gradually worsening disease caused by inflammation of the small 
blood vessels, called granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA): 
* Granulomatosis with polyangiitis mainly affects small blood vessels and tissues in the 
kidneys, lung, throat, nose and sinuses, but also other organs. Patients develop small lumps 
(granulomas) in and around blood vessels, which are formed by tissue damage caused by 
inflammation. 
* Microscopic polyangiitis affects the smaller blood vessels. It often affects the kidneys but may 
also affect other organs. </p>
<p>Complement 5a receptor has a key role in stimulating inflammation. This medicine attaches to it and 
prevents it from working, thereby reducing inflammation of blood vessels seen in these diseases. </p>
<p>Tavneos can be used together with other treatments prescribed by your doctor. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take tavneos"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take tavneos"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Tavneos </p>
<ul>
<li>if you are allergic to avacopan or any of the other ingredients of this medicine (listed in 
section 6) </li>
</ul>
<p>Warnings and precautions </p>
<p>Talk to your doctor before taking Tavneos and during treatment if you had or have: 
* a liver disease such as increased levels of total bilirubin, the yellow breakdown substance of 
blood pigment, or of liver enzymes such as transaminases 
* any infection, unexpected bruising and bleeding (these two are common signs of bone marrow 
failure) 
* hepatitis B, hepatitis C, HIV infection or tuberculosis 
* a heart disease, such as heart attack, heart failure, inflammation of heart blood vessels 
* any type of cancer. </p>
<p>Tavneos is not recommended in patients with<br />
<em> an active liver disease, or<br />
</em> an active, serious infection. </p>
<p>Your doctor will carry out blood tests before and when necessary during treatment, to check: 
* any problems with your liver (by measuring liver enzymes and total bilirubin in the blood) 
* your risk of getting infections (by measuring the white blood cell count). 
Your doctor will decide to temporally stop or permanently discontinue treatment.  </p>
<p>Your doctor will also monitor you for signs and symptoms of an infection called Neisseria 
meningitidis. This is recommended for adult patients with GPA or MPA. </p>
<p>It is recommended that you have treatment to prevent the lung infection Pneumocystis jirovecii 
pneumonia during treatment with Tavneos. </p>
<p>It is recommended to give vaccinations before treatment with Tavneos or when there is no active 
disease (granulomatosis with polyangiitis or microscopic polyangiitis). </p>
<p>Severe and often painful swelling under the skin, mainly in the face, has been reported during 
treatment with Tavneos. If this affects the throat it can make it hard to breathe. Stop treatment and 
seek urgent medical advice if swelling of the face, lips, tongue or throat, or breathing difficulties 
occur. </p>
<p>Children and adolescents </p>
<p>Do not give this medicine to children under 18 years as there is not enough evidence to know if this 
medicine is safe and effective in this age group. </p>
<p>Other medicines and Tavneos </p>
<p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other 
medicines. </p>
<p>It is important to tell your doctor especially if you use any of the following medicines: 
* carbamazepine, phenobarbital, phenytoin: medicines to treat epilepsy and other illnesses 
* enzalutamide, mitotane: medicines to treat cancer 
* rifampicin, a medicine to treat tuberculosis or certain other infections 
* St. John s wort, an herbal medicine used for mild depression. 
If short-term use of one of these medicines cannot be avoided during treatment with Tavneos, your 
doctor may regularly check your condition to see how well Tavneos is working. </p>
<p>Tavneos can affect or be affected by the following medicines.<br />
<em> alfentanil: a painkiller used during an operation with anaesthetics 
* boceprevir, telaprevir: medicines to treat hepatitis C 
* bosentan: a medicine to treat high blood pressure in the lungs, and sores on the fingers and toes 
called scleroderma 
* clarithromycin, telithromycin: antibiotic medicines to treat bacterial infections 
* conivaptan: a medicine to treat low blood sodium levels 
* ciclosporin: a medicine to suppress the immune system and prevent transplant rejection, treat 
severe skin diseases and severe eye or joint inflammation 
* dabigatran: a blood thinning medicine 
* dihydroergotamine, ergotamine: medicines to treat migraine 
* fentanyl: a strong painkiller 
* indinavir, efavirenz, etravirine, lopinavir/ritonavir, nelfinavir, ritonavir, saquinavir: medicines to 
treat HIV infections 
* itraconazole, posaconazole, voriconazole: medicines to treat fungal infections 
* ketoconazole: a medicine to treat symptoms caused by the body s excessive production of 
cortisol called Cushing s syndrome 
* mibefradil: a medicine to treat irregular heart rhythm and high blood pressure 
* modafinil: a medicine to treat an extreme tendency to fall asleep 
* nefazodone: medicines to treat depression<br />
</em> sirolimus, tacrolimus: medicines to suppress the immune system and prevent transplant 
rejection. </p>
<p>Tavneos with food and drink </p>
<p>Avoid grapefruit and grapefruit juice during treatment with Tavneos, as these can influence the effect 
of the medicine. </p>
<p>Pregnancy and breast-feeding </p>
<p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask 
your doctor or pharmacist for advice before taking this medicine. </p>
<ul>
<li>Pregnancy 
This medicine is not recommended during pregnancy or in women of childbearing potential not 
using contraception. </li>
<li>Breast-feeding 
It is unknown whether avacopan passes into breast milk. A risk to the baby cannot be excluded. 
Your doctor will help you decide whether to stop treatment with Tavneos or stop breast-feeding. </li>
</ul>
<p>Driving and using machines </p>
<p>It is considered unlikely that Tavneos will affect your ability to drive or to use machines. </p>
<p>Tavneos contains macrogolglycerol hydroxystearate </p>
<p>This may cause stomach upset and diarrhoea. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take tavneos"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take tavneos"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor 
or pharmacist if you are not sure. </p>
<p>The recommended dose is 3 capsules in the morning and 3 capsules in the evening. </p>
<p>Method of administration </p>
<p>Swallow the capsules whole with one glass of water. Do not crush, chew or open the capsules. Take 
the capsules with a meal, 3 capsules in the morning and 3 capsules in the evening. </p>
<p>If you take more Tavneos than you should </p>
<p>Talk to your doctor immediately. </p>
<p>If you forget to take Tavneos </p>
<p>If you have more than 3 hours to go until your next scheduled dose, take the missed dose as soon as 
possible and then take your next dose at the right time. </p>
<p>If it is less than 3 hours to your next dose, do not take the missed dose. Just take your next dose at the 
usual time. </p>
<p>Do not take a double dose to make up for a forgotten dose. </p>
<p>If you stop taking Tavneos </p>
<p>Stop treatment and seek urgent medical advice if swelling of the face, lips, tongue or throat, or 
breathing difficulties occur. In any other situations, do not stop taking this medicine without talking to 
your doctor. </p>
<p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. </p>
<p>Contact your doctor immediately if the following serious side effects occur:<br />
Very common (may affect more than 1 in 10 people) 
* blood test showing increased levels of </p>
<p>liver enzymes (a sign of liver problems) </p>
<p>bilirubin: a yellow breakdown substance of the blood pigment. </p>
<p>Common (may affect up to 1 in 10 people)<br />
* lung inflammation (symptoms can be wheezing, difficulty breathing, or chest pain). </p>
<p>Uncommon (may affect up to 1 in 100 people) 
* serious allergic reaction which causes swelling under the skin, mainly in the face, and may 
cause breathing difficulties (angioedema). </p>
<p>Other side effects can occur with the following frequencies: 
Very common<br />
<em> infection of the upper airways 
* sore and inflamed throat and nose 
* headache 
* feeling sick (nausea)<br />
</em> diarrhoea 
* vomiting 
* decreased white blood cell count seen in blood tests. </p>
<p>Common<br />
* inflammation of the inner lining of the nose which causes sneezing, itching, runny and blocked 
nose 
* urinary tract infections 
* inflammation of the sinuses or bronchial tubes 
* inflammation of the stomach and bowel lining 
* infection of the lower airways 
* cellulitis 
* shingles 
* flu 
* Candida yeast fungal infection or herpes in the mouth 
* middle ear infection 
* reduced number of white blood cells called neutrophils (symptoms can be infections, fever or 
painful swallowing) 
* upper abdominal pain 
* increased blood level of creatine phosphokinase enzyme (symptoms can be chest pain, 
confusion, muscle ache and pain, sudden weakness or numbness of the body). </p>
<p>Reporting of side effects </p>
<p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects 
not listed in this leaflet. You can also report side effects directly via the national reporting system 
listed in Appendix V. By reporting side effects you can help provide more information on the safety of 
this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store tavneos"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store tavneos"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date which is stated on the carton and bottle after  EXP . 
The expiry date refers to the last day of that month. </p>
<p>This medicine does not require any special temperature storage conditions. Store in the original bottle 
in order to protect from light. </p>
<p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Tavneos contains </p>
<ul>
<li>The active substance is avacopan. 
Each hard capsule contains 10 mg of avacopan. </li>
<li>The other ingredients are: </li>
</ul>
<p>macrogolglycerol hydroxystearate </p>
<p>macrogol (4000) </p>
<p>gelatin </p>
<p>polysorbate <br />
red iron oxide (E172), yellow iron oxide (E172), black iron oxide (E172) </p>
<p>titanium dioxide (E171) </p>
<p>shellac </p>
<p>potassium hydroxide. </p>
<p>What Tavneos looks like and contents of the pack </p>
<p>Tavneos hard capsules are made of a yellow body and light orange cap with  CCX168  in black ink. 
Capsules are 22 mm long, with a diameter of 8 mm. 
The capsules are packed in plastic bottles with a child-resistant closure. </p>
<p>Tavneos is available in 
* packs containing 30 hard capsules or<br />
<em> packs containing 180 hard capsules or<br />
</em> multipacks containing 540 hard capsules (3 individual packs of 180 hard capsules). </p>
<p>Not all pack sizes may be marketed. </p>
<p>Marketing Authorisation Holder </p>
<p>Vifor Fresenius Medical Care Renal Pharma France 
100 101 Terrasse Boieldieu 
Tour Franklin La D fense 8 
92042 Paris la D fense Cedex 
France </p>
<p>Manufacturer </p>
<p>Vifor France<br />
100 101 Terrasse Boieldieu<br />
Tour Franklin La D fense 8<br />
92042 Paris La D fense Cedex<br />
France </p>
<p>For any information about this medicine, please contact the Marketing Authorisation Holder. </p>
<p>This leaflet was last revised in </p>
<p>Other sources of information </p>
<p>Detailed information on this medicine is available on the European Medicines Agency website: 
http://www.ema.europa.eu. There are also links to other websites about rare diseases and treatments. </p>
<p>Detailed information on this medicine is also available on the following URL: http://www.tavneos-
patient.eu. </p>         </div>"""      



Instance: composition-da-74cee07ffddb72142d80fc4c20efe6f2
InstanceOf: CompositionUvEpi
Title: "Composition for tavneos Package Leaflet"
Description:  "Composition for tavneos Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpcda3d6c6b3d95392dfae933ed4fdbdcb)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - tavneos"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen </p>
<ol>
<li>Virkning og anvendelse </li>
<li>Det skal du vide, før du begynder at tage Tavneos </li>
<li>Sådan skal du tage Tavneos </li>
<li>Bivirkninger </li>
<li>Opbevaring </li>
<li>Pakningsstørrelser og yderligere oplysninger </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What tavneos is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What tavneos is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Hvad er Tavneos? </p>
<p>Tavneos indeholder det aktive stof avacopan, som bindes til et specifikt protein, kaldet komplement 
5a-receptor, i kroppen. </p>
<p>Hvad bruges Tavneos til? </p>
<p>Tavneos bruges til at behandle voksne med gradvist forværrende sygdom forårsaget af betændelse i de 
små blodkar, også kaldet granulomatose med polyangiitis (GPA) og mikroskopisk polyangiitis (MPA): </p>
<ul>
<li>
<p>Granulomatose med polyangiitis rammer hovedsageligt små blodkar og væv i nyrer, lunger, 
hals, næse og bihuler, men også andre organer. Patienterne udvikler små knuder (granuloma) i 
og omkring blodkar. Disse knuder er dannet af beskadiget væv, der skyldes betændelse. </p>
</li>
<li>
<p>Mikroskopisk polyangiitis rammer mindre blodkar. Den rammer ofte nyrerne, men kan også 
angribe andre organer. </p>
</li>
</ul>
<p>Komplement 5a-receptoren spiller en central rolle i stimuleringen af inflammation. Dette lægemiddel 
binder sig til denne receptor og forhindrer den i at virke. Derved reduceres den inflammation i 
blodkarrene, der kendetegner disse sygdomme. </p>
<p>Tavneos kan bruges i kombination med andre behandlinger ordineret af lægen. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take tavneos"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take tavneos"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke Tavneos </p>
<ul>
<li>hvis du er allergisk over for avacopan eller et af de øvrige indholdsstoffer i Tavneos (angivet i 
punkt 6). </li>
</ul>
<p>Advarsler og forsigtighedsregler </p>
<p>Kontakt lægen, før du tager Tavneos og under behandlingen, hvis du har haft eller har: </p>
<ul>
<li>
<p>en leversygdom som for eksempel forhøjet total bilirubin, som er det gule nedbrydningsstof i 
blodpigmentet, eller forhøjede leverenzymer som for eksempel transaminaser </p>
</li>
<li>
<p>en infektion, uventede blå mærker og blødninger (disse to symptomer er almindelige tegn på 
knoglemarvssvigt) </p>
</li>
<li>
<p>hepatitis B, hepatitis C, hiv-infektion eller tuberkulose </p>
</li>
<li>
<p>en hjertesygdom som f.eks. hjerteanfald, hjertesvigt eller betændelse i hjertets blodkar </p>
</li>
<li>
<p>enhver form for kræftsygdom. </p>
</li>
</ul>
<p>Tavneos bør ikke gives til patienter med </p>
<ul>
<li>
<p>en aktiv leversygdom eller </p>
</li>
<li>
<p>en aktiv, alvorlig infektion. </p>
</li>
</ul>
<p>Hvis nødvendigt vil lægen tage blodprøver før og under behandlingen for at kontrollere: </p>
<ul>
<li>
<p>om der er problemer med din lever (ved at måle leverenzymerne og total bilirubin i blodet) </p>
</li>
<li>
<p>din risiko for at få infektioner (ved at foretage en tælling af de hvide blodceller). 
Lægen vil beslutte, om behandlingen skal afbrydes midlertidigt eller permanent. </p>
</li>
</ul>
<p>Lægen vil også kontrollere dig for tegn og symptomer på en infektion kaldet Neisseria meningitidis. 
Dette anbefales hos voksne patienter med GPA og MPA.  </p>
<p>Det anbefales, at du modtager forebyggende behandling mod lungeinfektionen Pneumocystis jirovecii 
under behandlingen med Tavneos. </p>
<p>Det anbefales, at vaccinationer gives før behandling med Tavneos, eller når sygdommen ikke er aktiv 
(granulomatose med polyangiitis eller mikroskopisk polyangiitis). </p>
<p>Der er rapporteret om alvorlig og ofte smertefuld alvorlig hævelse under huden, navnlig i ansigtet, 
under behandling med Tavneos. Hvis der opstår hævelser i halsen, kan det give åndedrætsbesvær. Stop 
behandlingen, og søg omgående læge i tilfælde af hævelser i ansigtet, læberne, tungen eller halsen, 
eller hvis du oplever åndedrætsbesvær. </p>
<p>Børn og unge </p>
<p>Giv ikke denne medicin til børn og unge under 18 år, da der ikke foreligger tilstrækkelig evidens for, 
at denne medicin er sikker og virkningsfuld for denne aldersgruppe. </p>
<p>Brug af anden medicin sammen med Tavneos </p>
<p>Fortæl lægen eller apotekspersonalet, hvis du tager anden medicin, for nylig har taget anden medicin 
eller planlægger at tage anden medicin. </p>
<p>Navnlig er det vigtigt, at du fortæller lægen, hvis du tager nogen af de følgende lægemidler: </p>
<ul>
<li>
<p>carbamazepin, phenobarbital, phenytoin: medicin til behandling af epilepsi og andre sygdomme </p>
</li>
<li>
<p>enzalutamid, mitotan: medicin til behandling af kræft </p>
</li>
<li>
<p>rifampicin: et lægemiddel til behandling af tuberkulose eller visse andre infektioner </p>
</li>
<li>
<p>perikon: en plantemedicin brugt til behandling af mild depression. </p>
</li>
</ul>
<p>Hvis det ikke er muligt at undgå kort tids behandling med et af disse lægemidler under behandlingen 
med Tavneos, kan lægen regelmæssigt kontrollere din tilstand for at se, hvor godt Tavneos virker. </p>
<ul>
<li>
<p>Tavenos kan påvirke eller blive påvirket af de følgende lægemidler: </p>
</li>
<li>
<p>alfentanil: et smertestillende middel, der bruges med narkosemidler under en operation </p>
</li>
<li>
<p>boceprevir, telaprevir: lægemidler til behandling af hepatitis C </p>
</li>
<li>
<p>bosentan: et lægemiddel til behandling af højt blodtryk i lungerne og sår på fingre og tæer, som 
kaldes scleroderma </p>
</li>
<li>
<p>clarithromycin, telithromycin: antibiotika til behandling af bakterieinfektioner </p>
</li>
<li>
<p>conivaptan: medicin til behandling af lave natriumværdier i blodet </p>
</li>
<li>
<p>ciclosporin: et lægemiddel, som undertrykker immunsystemet og bruges til at forebygge 
afstødning af transplantater, behandle svære hudsygdomme og svær øjen- eller ledbetændelse </p>
</li>
<li>
<p>dabigatran: en blodfortyndende medicin </p>
</li>
<li>
<p>dihydroergotamin, ergotamin: lægemidler, der bruges til behandling af migræne </p>
</li>
<li>
<p>fentanyl: et stærkt smertestillende middel </p>
</li>
<li>
<p>indinavir, efavirenz, etravirin, lopinavir/ritonavir, nelfinavir, ritonavir, saquinavir: lægemidler til 
behandling af hiv-infektioner </p>
</li>
<li>
<p>itraconazol, posaconazol, voriconazol: lægemidler, der bruges til behandling af 
svampeinfektioner </p>
</li>
<li>
<p>ketoconazol: lægemiddel til behandling af symptomer forårsaget af kroppens overdrevne 
produktion af cortisol, også kaldet Cushings syndrom </p>
</li>
<li>
<p>mibefradil: lægemiddel til behandling af uregelmæssig hjerterytme og højt blodtryk </p>
</li>
<li>
<p>modafinil: lægemiddel til behandling af ekstrem tendens til at falde i søvn </p>
</li>
<li>
<p>nefazodon: lægemidler til behandling af depression </p>
</li>
<li>
<p>sirolimus, tacrolimus: lægemidler til undertrykkelse af immunsystemet og forebyggelse af 
afstødning af transplantat </p>
</li>
</ul>
<p>Brug af Tavneos sammen med mad og drikke </p>
<p>Undgå grapefrugt og grapefrugtjuice, mens du er i behandling med Tavneos, da disse kan påvirke 
virkningen af medicinen. </p>
<p>Graviditet og amning </p>
<p>Hvis du er gravid eller ammer, har mistanke om, at du er gravid, eller planlægger at blive gravid, skal 
du spørge din læge eller apotekspersonalet til råds, før du tager dette lægemiddel. </p>
<ul>
<li>
<p>Graviditet 
Tavneos bør ikke anvendes til gravide og kvinder i den fødedygtige alder, som ikke anvender 
prævention. </p>
</li>
<li>
<p>Amning 
Det vides ikke, om avacopan udskilles i modermælk. En risiko for spædbarnet kan ikke 
udelukkes. Lægen vil hjælpe dig med at beslutte, om du skal stoppe behandlingen med Tavneos 
eller stoppe med at amme. </p>
</li>
</ul>
<p>Trafik- og arbejdssikkerhed </p>
<p>Det anses for usandsynligt, at Tavneos påvirker evnen til at føre motorkøretøj eller betjene maskiner. </p>
<p>Tavneos indeholder macrogolglycerolhydroxystearat. </p>
<p>Dette stof kan forårsage "ondt i maven" og diarré. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take tavneos"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take tavneos"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid lægemidlet nøjagtigt efter lægens eller apotekspersonalets anvisning. Er du i tvivl, så spørg 
lægen eller apotekspersonalet. </p>
<p>Den anbefalede dosis er 3 kapsler om morgenen og 3 kapsler om aftenen. </p>
<p>Indtagelse </p>
<p>Synk kapslerne hele med et glas vand. Kapslerne må ikke knuses, tygges eller åbnes. Indtag kapslerne 
under et måltid: 3 kapsler om morgenen og 3 kapsler om aftenen. </p>
<p>Hvis du har taget for meget Tavneos </p>
<p>Kontakt straks lægen. </p>
<p>Hvis du har glemt at tage Tavneos </p>
<p>Hvis der er mere end 3 timer til den næste planlagte dosis, skal du tage den glemte dosis så hurtigt 
som muligt og derefter den næste dosis på det samme tidspunkt som normalt. </p>
<p>Hvis der er mindre end 3 timer til din næste dosis, skal du ikke tage den glemte dosis. Du skal blot 
tage den næste dosis på samme tidspunkt som normalt. </p>
<p>Du må ikke tage en dobbeltdosis som erstatning for den glemte dosis. </p>
<p>Hvis du holder op med at tage Tavneos </p>
<p>Stop behandlingen, og søg omgående læge, hvis du oplever hævelser i ansigt, læber, tunge eller hals 
eller åndedrætsbesvær. Stop ikke med at tage dette lægemiddel af andre grunde uden at drøfte det med 
din læge. </p>
<p>Spørg lægen eller apotekspersonalet, hvis der er noget, du er i tvivl om. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger. </p>
<p>Kontakt straks din læge, hvis en eller flere af følgende alvorlige bivirkninger opstår: 
Meget almindelig (kan forekomme hos mere end 1 ud af 10 personer) </p>
<ul>
<li>blodprøver, der viser forøget indhold af 
– 
leverenzymer (et tegn på leversygdomme) 
– 
bilirubin: et gult stof, der dannes ved nedbrydning af blodpigment. </li>
</ul>
<p>Almindelig (kan forekomme hos op til 1 ud af 10 personer) </p>
<ul>
<li>lungebetændelse (symptomer herpå kan være hvæsende vejrtrækning, åndedrætsbesvær eller 
brystsmerter).  </li>
</ul>
<p>Ikke almindelige (kan forekomme hos op til 1 ud af 100 personer) </p>
<ul>
<li>alvorlig allergisk reaktion, der forårsager hævelse under huden, fortrinsvis i ansigtet, og som 
kan forårsage åndedrætsbesvær (angioødem). </li>
</ul>
<p>Der kan opstå andre bivirkninger med følgende hyppigheder: 
Meget almindelige  </p>
<ul>
<li>
<p>infektion i de øvre luftveje </p>
</li>
<li>
<p>øm og betændt hals og næse </p>
</li>
<li>
<p>hovedpine </p>
</li>
<li>
<p>ubehag (kvalme) </p>
</li>
<li>
<p>diarré </p>
</li>
<li>
<p>opkastning </p>
</li>
<li>
<p>nedsat antal hvide blodlegemer i blodprøver. </p>
</li>
</ul>
<p>Almindelige </p>
<ul>
<li>
<p>betændelse i slimhinden i næsen, hvilket udløser nysen, kløe samt løbende og tilstoppet næse </p>
</li>
<li>
<p>urinvejsinfektioner </p>
</li>
<li>
<p>betændelse i bihuler eller bronkier </p>
</li>
<li>
<p>betændelse i mave- og tarmslimhinde </p>
</li>
<li>
<p>infektion af de nedre luftveje </p>
</li>
<li>
<p>cellulitis </p>
</li>
<li>
<p>helvedesild </p>
</li>
<li>
<p>influenza </p>
</li>
<li>
<p>Candida gærsvampeinfektion eller herpes i munden </p>
</li>
<li>
<p>mellemørebetændelse </p>
</li>
<li>
<p>nedsat antal hvide blodlegemer kaldet neutrofiler (symptomer kan være infektioner, feber eller 
synkesmerter) </p>
</li>
<li>
<p>øvre mavesmerter </p>
</li>
<li>
<p>blodprøver, der viser forhøjet indhold af kreatinfosfokinaseenzym (symptomerne kan være 
brystsmerter, forvirring, muskelømhed og -smerter, pludselig svaghed eller følelsesløshed i 
kroppen). </p>
</li>
</ul>
<p>Indberetning af bivirkninger </p>
<p>Hvis du oplever bivirkninger, bør du tale med din læge eller apotekspersonalet. Dette gælder også 
mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende kan også 
indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem anført i 
Appendix V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere information om 
sikkerheden af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store tavneos"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store tavneos"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Brug ikke lægemidlet efter den udløbsdato, der står på kartonen og beholderen efter "EXP". 
Udløbsdatoen er den sidste dag i den nævnte måned. </p>
<p>Der er ingen særlige krav vedrørende opbevaringstemperaturer for dette lægemiddel. Opbevares i det 
originale glas for at beskytte mod lys. </p>
<p>Spørg apotekspersonalet, hvordan du skal bortskaffe medicinrester. Af hensyn til miljøet må du ikke 
smide medicinrester i afløbet, toilettet eller skraldespanden. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tavneos indeholder: </p>
<ul>
<li>
<p>Aktivt stof: avacopan. 
 Hver hård kapsel indeholder 10 mg avacopan. </p>
</li>
<li>
<p>Øvrige indholdsstoffer: 
– 
macrogolglycerolhydroxystearat 
– 
macrogol (4000) 
– 
gelatine 
– 
polysorbat – 
rød jerndioxid (E172), gul jernoxid (E172), sort jernoxid (E172) 
– 
titandioxid (E171) 
– 
shellak 
– 
kaliumhydroxid. </p>
</li>
</ul>
<p>Udseende og pakningsstørrelser </p>
<p>Tavneos hårde kapsler med gul krop og lys orange hætte med "CCX168" præget med sort blæk. 
Kapslerne er 22 mm lange med en diameter på 8 mm. 
Kapslerne er pakket i plastikflasker med børnesikret lukning. </p>
<p>Tavneos fås i  </p>
<ul>
<li>
<p>pakninger med 30 hårde kapsler eller  </p>
</li>
<li>
<p>pakninger med 180 hårde kapsler eller  </p>
</li>
<li>
<p>multipakninger med 540 hårde kapsler (3 individuelle pakninger à 180 hårde kapsler). </p>
</li>
</ul>
<p>Ikke alle pakningsstørrelser er nødvendigvis markedsført. </p>
<p>Indehaver af markedsføringstilladelsen </p>
<p>Vifor Fresenius Medical Care Renal Pharma France 
100–101 Terrasse Boieldieu 
Tour Franklin La Défense 8 
92042 Paris la Défense Cedex 
Frankrig </p>
<p>Fremstiller </p>
<p>Vifor France 
100–101 Terrasse Boieldieu 
Tour Franklin La Défense 8 
92042 Paris La Défense Cedex 
Frankrig </p>
<p>For yderligere oplysninger om dette lægemiddel bedes du kontakte indehaveren af 
markedsføringstilladelsen. </p>
<p>Denne indlægsseddel blev senest ændret </p>
<p>Andre informationskilder </p>
<p>Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside http://www.ema.europa.eu. Der er også links til andre websteder om sjældne sygdomme 
og om, hvordan de behandles. </p>
<p>Du kan finde yderligere oplysninger om dette lægemiddel på hjemmesiden http://www.tavneos-
patient.eu. </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-74cee07ffddb72142d80fc4c20efe6f2
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for tavneos Package Leaflet for language en"
Description: "ePI document Bundle for tavneos Package Leaflet for language en"
Usage: #example




* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-74cee07ffddb72142d80fc4c20efe6f2"
* entry[0].resource = composition-en-74cee07ffddb72142d80fc4c20efe6f2

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp74cee07ffddb72142d80fc4c20efe6f2"
* entry[=].resource = mp74cee07ffddb72142d80fc4c20efe6f2
                            
                    
Instance: bundlepackageleaflet-da-74cee07ffddb72142d80fc4c20efe6f2
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for tavneos Package Leaflet for language da"
Description: "ePI document Bundle for tavneos Package Leaflet for language da"
Usage: #example




* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-74cee07ffddb72142d80fc4c20efe6f2"
* entry[0].resource = composition-da-74cee07ffddb72142d80fc4c20efe6f2

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp74cee07ffddb72142d80fc4c20efe6f2"
* entry[=].resource = mp74cee07ffddb72142d80fc4c20efe6f2
                            
                    



Instance: mp74cee07ffddb72142d80fc4c20efe6f2
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product tavneos"
Description: "tavneos"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/21/1605/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"


* indication = "Tavneos, in combination with a rituximab or cyclophosphamide regimen, is indicated for the treatment"


* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"


* name
  * productName = "tavneos"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#DK "DK"
    * jurisdiction = urn:iso:std:iso:3166#DK "DK"
    * language = urn:ietf:bcp:47#en  "en"




RuleSet: 74cee07ffddb72142d80fc4c20efe6f2ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "tavneos"

* status = #current
* mode = #working

* title = "List of all ePIs associated with tavneos"

* subject = Reference(mpcda3d6c6b3d95392dfae933ed4fdbdcb)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#tavneos "tavneos"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-74cee07ffddb72142d80fc4c20efe6f2) // tavneos en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-74cee07ffddb72142d80fc4c20efe6f2) // tavneos da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-74cee07ffddb72142d80fc4c20efe6f2
InstanceOf: List

* insert 74cee07ffddb72142d80fc4c20efe6f2ListRuleset
    